Trial Profile
A Phase II Study of Pembrolizumab in Patients With Advanced Gynaecological Clear Cell Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms PEACOCC
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 22 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Feb 2019 Status changed from not yet recruiting to recruiting.